CALR-targeted therapies and the MF transplant paradigm
Current understanding
To be populated as evidence accumulates.
Evidence log
Open questions
Related
Contributing findings
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
23-oct-2026
novelty 2
per-area 3
strengthens
How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?
23-oct-2026
novelty 2
per-area 3
introduces